RAP1A suppresses hepatic steatosis by regulating amino acid-mediated mTORC1 activation
Metabolic dysfunction-associated liver pathologies are inadequately treated with currently available therapy. Here we demonstrate that the small GTPase RAS-associated protein 1A (RAP1A) protects against liver steatosis and fibrosis development by decreasing hepatocyte amino acid levels, which results in lower mTORC1 activity and SREBP1 cleavage. The results may present new targets against metabolic dysfunction related liver diseases.
Authors
- Lale Özcan (ORCID: https://orcid.org/0000-0002-2710-7057)
- Xiaobo Wang (ORCID: https://orcid.org/0000-0001-6044-914X)
- Yating Wang (ORCID: https://orcid.org/0009-0004-8204-7626)
- Brea Tinsley (ORCID: https://orcid.org/0000-0002-5404-5832)
- Heena Agarwal
Institutions
- Central South University (CN)
- Columbia University Irving Medical Center (US)
- Center for Digestive and Liver Diseases (US)
- Second Xiangya Hospital of Central South University (CN)
- Columbia University (US)
Publication Details
- Journal
- JHEP Reports
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.jhepr.2024.101303
- Citations
- 4
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- American Heart Association
- Georgia Clinical and Translational Science Alliance
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- National Institutes of Health